ChemoCentryx, Inc.

While regulatory uncertainty in the US is mounting, Amgen does not expect significant revenue impact from new tariffs implemented under US President Donald Trump, chief financial officer Peter Griffit

Amgen, Inc. previously specialized in large therapeutic areas like cardiovascular diseases and inflammation, but added a big focus on medicines for rare diseases through its $27.8bn acquisition of H

Last week, Novartis AG ’s complement factor B inhibitor iptacopan scored an approval in paroxysmal nocturnal hemoglobinuria (PNH) under the name Fabhalta. Today it posted a different type of success,

Dealmaking will continue to pick up in 2023, but don’t expect mega-mergers. That’s the message from many industry-watchers, chastened by a largely forgettable 2022 that failed to deliver the expected